Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Pasquale Forgione

Jean Rancourt

Montse Llinas-Brunet

Murray D Bailey

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

Punit R Bhardwaj

Pierre Louis Beaulieu

Martin Poirier

Marc-Andre Poupart

Marc-André Poupart

Sylvie Goulet

Julie Naud

Alexandre Gagnon

Vida J Gorys

Marc-Andre Joly

Josee Bordeleau

Francois Bilodeau

François Bilodeau

Punit K Bhardwaj

Compounds of formula I: wherein X, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Viral polymerase inhibitors

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Compounds of formula (I): wherein R, R, X, R, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

The invention relates to compounds of formula (I) wherein R', R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I). 

Hepatitis C inhibitor peptide analogs

Growing community of inventors

Montreal, Canada

Pasquale Forgione